Effect of amorphous content on dissolution characteristics of rifampicin

Drug Development and Industrial Pharmacy

Volumn 34, Issue 6, 2008, Pages 642-649

  Panchagnula, Ramesh ^a,b   Bhardwaj, Vivekanand ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b RRR LABS PVT LTD   (India)

Author keywords

Amorphous; Intrinsic dissolution rate; Rifampicin; Solid state characterization

Indexed keywords

RIFAMPICIN;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SYNTHESIS; SOLID STATE;

ANTIBIOTICS, ANTITUBERCULAR; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; KINETICS; POWDERS; RIFAMPIN; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMOGRAVIMETRY;

EID: 45849152090     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701842451     Document Type: Article

References (11)

1. Agrawal, S., Ashokraj, Y., Bharatam, P. V., Pillai, O., & Panchagnula, R. (2004). Solid state characterization of rifampicin samples and its biopharmaceutic relevance. Eur. J. Pharm. Sci., 22, 127-144.
2. Agrawal, S., & Panchagnula, R. (2004). In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms. Pharmazie, 59, 775-781.
3. Bauer, M., de Leede, L., & Van Der Waart, M. (1998). Purity as an issue in pharmaceutical research and development. Eur. J. Pharm. Sci., 6, 331-335.
4. Gallo, C. G., & Radaelli, P. (1976). Rifampicin. In K. Florey (Ed.), Analytical profiles of drug substances (pp. 467-513). London: Academic press.
5. Gandhi, R., Pillai, O., Thilagavathi, R., Gopalakrishnan, B., Kaul, C. L., & Panchagnula, R. (2002). Characterization of azithromycin hydrates. Eur. J. Pharm. Sci., 16, 175-184.
6. Henwood, S. Q., de Villiers, M. M., Liebenberg, W., & Lotter, A. P. (2000). Solubility and dissolution properties of generic rifampicin raw materials. Drug Dev. Ind. Pharm., 26, 403-408.
7. Henwood, S. Q., Liebenberg, W., Tiedt, L. R., Lotter, A. P., & de Villiers, M. M. (2001). Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates. Drug Dev. Ind. Pharm., 27, 1017-1030.
8. Lindenberg, M., Kopp, S., & Dressman, J. B. (2004). Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm., 58, 265-278.
9. Pahkla, R., Lambert, J., Ansko, P., Winstanley, P., Davies, P. D. O., & Kiivet, R.-A. (1999). Comparative bioavailability of three different preparations of rifampicin. J. Clin. Pharm. Ther., 24, 219-225.
10. Panchagnula, R., Prakash, S., Pillai, O., Agrawal, S., & Ashokraj, Y. (2004). Solid state characterization of mefenamic acid. J. Pharm. Sci., 93(4), 1019-1029.
11. Pelizza, G., Nebuloni, M., Ferrari, P., & Gallo, G. (1977). Polymorphism of rifampicin. Farmaco, 32, 471-481.